NAD+

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular energy and longevity research. It is present in every living cell, shuttles electrons through metabolism, and acts as the obligate co-substrate for sirtuins, PARPs and CD38. JCSG.org supplies research-grade Body Pharm NAD+ precursors to United Arab Emirates laboratories for laboratory research use only — not for human or veterinary use.

Our peptides

Body Pharm NAD+ 1000 Pen — a 1000 mg NAD+ pen delivering selectable 10/20/30 mg increments for cellular energy and longevity research. Live AED pricing is shown in the buy box on the product page.

Key takeaways

• NAD+ is a coenzyme that declines with age, driving reduced sirtuin activity and linked to metabolic and mitochondrial dysfunction in preclinical models.
• The NAD+/NADH ratio, not absolute NAD+, is the signal that dehydrogenases, sirtuins and metabolic regulators actually sense.
• More than 85% of daily NAD+ turnover in most tissues is recycled through the NAMPT salvage pathway rather than synthesised from scratch.
• Human trials reliably raise blood NAD+ at trial doses but lack large randomised trials proving hard clinical outcomes.
• The Body Pharm NAD+ 1000 pen is supplied as a research reagent alongside adjacent mitochondrial compounds such as MOTS-C.

What is NAD+? A plain-language definition

NAD+ is a small dinucleotide built from nicotinamide and adenine, joined through two ribose sugars and a phosphate bridge. That structure lets the nicotinamide ring accept and release hydride ions — the chemical basis for its electron-shuttling role. It is not a vitamin, not a hormone and not a peptide; it is a coenzyme found in every cell that accepts and donates electrons during metabolism and is consumed as a substrate by sirtuins, PARPs and CD38.

Four related molecules are frequently blurred, and the distinctions matter:

• NAD+ — the oxidised form; accepts electrons in catabolism (glycolysis, the citric acid cycle, fatty-acid oxidation) and is consumed by sirtuins and CD38.
• NADH — the reduced form; carries electrons to the mitochondrial electron transport chain to drive ATP synthesis.
• NADP+ — NAD+ with an extra phosphate group; used in anabolic and antioxidant chemistry rather than energy extraction.
• NADPH — the reduced form of NADP+; supplies reducing power for lipid and nucleotide synthesis and regenerates glutathione.

The "+" is not decoration. It denotes the oxidation state of the nicotinamide ring: NAD+ has a positively charged nitrogen that can accept a hydride ion to become NADH.

The NAD+/NADH redox cycle explained

NAD+ is the cell's principal electron shuttle. Its nicotinamide ring accepts a hydride ion (two electrons plus a proton) to become NADH, then hands those electrons off downstream to regenerate NAD+. Repeated millions of times per cell per second, this back-and-forth links food oxidation to ATP synthesis. Cells cannot store energy as free electrons; they must package it into the NAD+/NADH pair and pass it along a chain of carriers until oxygen, the final acceptor, is reached.

Three catabolic stages depend on this cycling. Glycolysis, in the cytosol, reduces NAD+ to NADH as glyceraldehyde-3-phosphate is oxidised. The tricarboxylic acid cycle, in the mitochondrial matrix, generates further NADH at the isocitrate, alpha-ketoglutarate and malate dehydrogenase steps. Oxidative phosphorylation then uses Complex I of the electron transport chain to strip electrons from NADH and drive ATP synthase.

Why the ratio matters

The absolute amount of NAD+ in a cell is less informative than the NAD+/NADH ratio, because that ratio is the signal sensed by dehydrogenases, sirtuins and metabolic regulators. A high cytosolic ratio indicates spare oxidising capacity and permits continued glycolytic flux; a collapsed ratio signals reductive stress and stalls catabolism. Sirtuins, which consume NAD+ stoichiometrically when they deacylate target proteins, are effectively reading this ratio as a fuel gauge.

NAD+ and sirtuins: the ageing connection

Sirtuins are NAD+-dependent deacylase enzymes (SIRT1–SIRT7) that consume NAD+ stoichiometrically as a co-substrate rather than recycling it as a cofactor. Every deacylation reaction permanently spends one NAD+ molecule and releases nicotinamide. That stoichiometric consumption is the mechanistic basis for linking declining cellular NAD+ pools to falling sirtuin activity, and in turn to the age-associated phenotypes that dominate longevity research.

SIRT1 and SIRT3 are the most-studied isoforms in ageing contexts. SIRT1 deacetylates transcription factors including p53, FOXO3 and PGC-1alpha, modulating DNA repair, inflammation and metabolic adaptation. SIRT3 is the principal mitochondrial deacetylase, regulating oxidative phosphorylation efficiency and the antioxidant response. The prevailing model runs as follows: NAD+ falls with age, driven partly by rising CD38 hydrolase activity and partly by reduced NAMPT-mediated salvage; sirtuins become substrate-limited; deacylation of their targets slows. The preclinical support is substantial in rodents and invertebrates, but human evidence that precursor supplementation rescues sirtuin-dependent endpoints — rather than simply raising blood NAD+ — remains thin. Animal lifespan findings should not be presented as established human outcomes.

How the body makes NAD+: the NAMPT salvage pathway

The body produces NAD+ through three routes. De novo synthesis from tryptophan via the kynurenine pathway is metabolically expensive and contributes only a small fraction of the steady-state pool. The Preiss–Handler pathway converts dietary nicotinic acid into the NAD+ pool and remains relevant wherever niacin intake is adequate. The salvage pathway recycles nicotinamide released whenever sirtuins, PARPs or CD38 cleave NAD+ during their catalytic cycles.

NAMPT — nicotinamide phosphoribosyltransferase — is the rate-limiting enzyme of the salvage pathway. Its catalytic step sets the ceiling on how fast nicotinamide can re-enter the NAD+ pool. When NAMPT activity falls, salvage flux falls with it, and intracellular NAD+ drops even if dietary B3 intake is unchanged. Two factors press on NAMPT with age: intracellular NAMPT expression declines in adipose, skeletal muscle and liver in rodent ageing models, and chronic low-grade inflammation alters the NAMPT balance. This is why precursor strategies targeting downstream of NAMPT are theoretically attractive — they bypass the bottleneck and can restore NAD+ even if NAMPT activity is impaired.

What researchers study

Human evidence for NAD+ precursor supplementation is consistent on one point and inconclusive on most others: oral precursors reliably raise blood NAD+ from baseline at trial doses. Raising a biomarker is not the same as improving a clinical outcome, and no large randomised trial has established any NAD+ precursor as a licensed treatment for fatigue, metabolic disease, cognitive decline or sarcopenia. For research purposes, that ceiling frames every downstream question.

The strongest mechanistic signal sits in metabolic health, where small trials report improvements in insulin sensitivity and muscle insulin signalling alongside neutral effects on body composition. Cognitive trials are early-stage and largely null on cognitive endpoints despite measurable peripheral NAD+ rises. Muscle-function and exercise results are mixed. In each case, biochemical NAD+ elevation is measurable, but hard-outcome data are not yet available.

Long-term cancer, cardiovascular and mortality data for high-dose NAD+ precursors in humans are not yet available. That absence is a genuine limitation for anyone weighing the risk-benefit picture, because NAD+-dependent enzymes are involved in DNA repair and cell-cycle control. For research use only — none of this constitutes medical advice.

NAD+ in structural biology and peptide research

NAD+ is both a redox cofactor and a structural ligand recognised by a conserved Rossmann-like fold present across hundreds of dehydrogenases, sirtuins and ADP-ribosyl transferases. That fold — a beta-alpha-beta-alpha-beta motif binding the dinucleotide in an extended conformation — is one of the most thoroughly catalogued ligand-binding architectures known, which is why NAD+-dependent enzymes featured heavily in early structural genomics target lists, including work at the Joint Center for Structural Genomics.

Three enzyme families dominate the therapeutic conversation. Sirtuins cleave the nicotinamide–ribose bond during substrate turnover. PARPs use NAD+ as the donor for poly-ADP-ribosylation during DNA damage response. CD38 is an NAD+ glycohydrolase whose rising expression with age is one proposed driver of tissue NAD+ decline. Resolving how NAD+ docks into these active sites tells designers exactly where a competitive peptide must sit, which side chains to mimic, and which sub-pockets tolerate substitution. Read this way, NAD+ is less a "supplement molecule" than a recurrent structural motif whose binding pockets define a large slice of the druggable proteome.

The Body Pharm NAD+ 1000 pen

The Body Pharm NAD+ 1000 pen carries 1000 mg of total reserve and delivers selectable 10, 20 or 30 mg increments, which suits dose-response work and extended study windows without mid-study re-ordering. As with any research reagent, request the batch-specific Certificate of Analysis confirming purity and identity before ordering, and verify the per-increment output against the supplier datasheet rather than assuming it from the product page.

Handling and storage

Lyophilised material is held cold for long-term storage; reconstituted or pre-mixed solution is kept refrigerated at 2–8 °C, protected from light, and should not be frozen once in the liquid state. Aliquot to avoid repeated freeze-thaw cycles where a lyophilised format is used. Log the lot number and CoA reference in the institutional reagent register for traceability.

Regulatory context in the UAE

NAD+ and its precursors are supplied by JCSG.org strictly as research chemicals for in vitro and preclinical laboratory use, not as medicines or food supplements for human consumption. Importation and domestic distribution fall under the relevant national health-authority oversight, and research-use or free-zone labelling does not exempt an entity from that oversight or from customs review. Confirm classification with your institutional compliance officer before raising a purchase order. This page is not legal advice.

Range placement

NAD+ sits with the mitochondrial and metabolic peptides in the JCSG.org UAE catalogue. The closest mechanistic neighbour is MOTS-C, which converges on AMPK and sirtuin signalling in preclinical mitochondrial models. Adjacent research tools include tissue-repair peptides BPC-157 and TB500, the growth-hormone-axis peptides CJC-1295 and ipamorelin, and the metabolic lead compound retatrutide.

Frequently asked questions